Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer

Inclusion Criteria

• •2\. Patients must be deemed unresectable due to involvement of critical vasculature, adjacent organ invasion, presence of metastasis, or other medical condition making surgical resection unfavorable.
• •3\. Patients must have a primary or metastatic lesion measurable in at least one dimension by RECIST criteria within 4 weeks prior to entry of study 4. More than 4 weeks must have elapsed from the time of major surgery or completion of the last dose of chemotherapy, radiation therapy, investigational therapy and patients must adequately recover from these effects.
• •5\. Life expectancy of \>3 months. 6. Karnofsky performance status \>70%. 7. Patients must have normal organ and marrow functions as defined below: absolute neutrophil count \>1,500/mm3 platelets \>70,000/mm3 total bilirubin \<1.5 mg/dL AST(SGOT)/ALT(SGPT) \<2.5 X institutional upper limit of normal creatinine within normal institutional limits OR creatinine clearance \>60mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
• •albumin \> 2.8 mg/dL 8. Patients must have adequate clotting function (platelet \> 70k; INR\<1.4; PTT\<60).
• •9\. Age \>18 years. 10. The effects of DCs on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.